{
    "clinical_study": {
        "@rank": "134429", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive Chidamide 20mg orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred."
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of Chidamide combined with\n      paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer."
        }, 
        "brief_title": "Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small-cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histology or cytology confirmed non-small-cell lung cancer,stage IIIb\n             or IV. Newly diagnosed or relapsed after surgery but have not received systemic drug\n             therapy.Adjuvant chemotherapy after surgery should have completed for more than one\n             year at study entry.\n\n          -  Aged 18~75 years\n\n          -  Epidermal growth factor receptor (EGFR) mutation negative or EGFR status is unknown\n\n          -  With at least one measurable lesion\n\n          -  White blood cell count\u22654\u00d710^9/L,platelet count\u2265100\u00d710^9/L and hemoglobin\u226511g/L\n\n          -  Life expectancy \uff1e3 months\n\n          -  Eastern Cooperative Oncology Group performance status of \u22641 at study entry\n\n          -  Women of childbearing age should have pregnancy test negative and would like to\n             conduct birth control during the study\n\n          -  Have signed informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with clinically significant corrected QT interval prolongation, or\n             ventricular tachycardia,or auricular fibrillation, or \u2265Grade 2 sino-auricular\n             heart-block,or \u2265Grade 3 atrioventricular block,or myocardial infarction within one\n             year, or congestive heart failure,or patients with symptomatic coronary disease which\n             need to be treated by drug\n\n          -  The size of fluid area detected by cardiac ultrasonography in cavum pericardium is\n             \u226510mm during diastolic period\n\n          -  Organ transplant patients\n\n          -  Patients with active bleeding or new thrombotic diseases\n\n          -  Patients with body temperature \uff1e38.5\u2103 for more than 3 days\n\n          -  Total bilirubin \uff1e1.5 fold of upper limit of normal (ULN), ALT/AST\uff1e1.5 fold of ULN or\n             serum creatine \uff1e1.5 fold of ULN\n\n          -  Patients with symptomatic brain-metastasis\n\n          -  Pregnant or lactating women\n\n          -  Patients with mental disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836679", 
            "org_study_id": "CDM204"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "Given orally", 
                "intervention_name": "Chidamide", 
                "intervention_type": "Drug", 
                "other_name": "CS055"
            }, 
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2"
                ], 
                "description": "Given IV", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Taxol", 
                    "TAX"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2"
                ], 
                "description": "Given IV", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CBDCA", 
                    "Paraplatin"
                ]
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "Given orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "PLB"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Chidamide,lung cancer", 
        "lastchanged_date": "April 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100021"
                    }, 
                    "name": "Cancer Hospital, Chinese Academy of Medical Sciences"
                }, 
                "investigator": {
                    "last_name": "Yuankai Shi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "101149"
                    }, 
                    "name": "Beijing Chest Hospital, Capital Medical University"
                }, 
                "investigator": {
                    "last_name": "Shucai Zhang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China", 
                        "state": "Hebei", 
                        "zip": "050011"
                    }, 
                    "name": "Hebei Provincial Tumor Hospital"
                }, 
                "investigator": {
                    "last_name": "Cuimin Ding", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210009"
                    }, 
                    "name": "Jiangsu Cancer Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Jifeng Feng", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Meiqi Shi", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning", 
                        "zip": "110001"
                    }, 
                    "name": "The first Hospital of China Medical University"
                }, 
                "investigator": {
                    "last_name": "Yunpeng Liu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200030"
                    }, 
                    "name": "Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University"
                }, 
                "investigator": {
                    "last_name": "Baohui Han", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "82816"
                    }, 
                    "name": "The Second People's Hospital of Sichuan"
                }, 
                "investigator": {
                    "last_name": "Ping Yu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300060"
                    }, 
                    "name": "Tianjin Medical University Cancer Institute & Hospital"
                }, 
                "investigator": {
                    "last_name": "Kai Li", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Study of Chidamide or Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer", 
        "overall_contact": {
            "email": "guoxia@chipscreen.com", 
            "last_name": "Xia Guo"
        }, 
        "overall_official": {
            "affiliation": "Cancer Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Yuankai Shi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PFS is measured from the start of treatment until progression or death,whichever is first met", 
            "measure": "Progression-Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 76 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836679"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "6-M-PFS is defined as the percentage of participants whose disease is still progression-free at the 6th month", 
                "measure": "Progression-Free Survival Rate at 6 Months (6-M-PFS)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "ORR is defined as percentage of participants with Complete Response and Partial Response,assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "measure": "Object Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Response is assessed once every 6 weeks (combination therapy period) for up to 12 weeks, and once every 8 weeks (maintenance therapy period) for up to 64 weeks"
            }, 
            {
                "description": "DOR is measured from the first date when criteria for response is met until the first date when the criteria for progression is met", 
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "From the first date of response until the date of first documented progression, assessed up to 70 weeks"
            }, 
            {
                "description": "OS is measured from the start of treatment until death", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of death from any cause, followed for up to 76 weeks"
            }, 
            {
                "description": "TTP is assessed for patients who complete the 12 weeks of combination therapy. It is measured from the start of maintenance therapy until the criteria of progression is met", 
                "measure": "Time To Progression (TTP) during the maintenance therapy period", 
                "safety_issue": "No", 
                "time_frame": "From the start date of maintenance therapy until the date of first documented progression, assessed up to 64 weeks"
            }
        ], 
        "source": "Chipscreen Biosciences, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chipscreen Biosciences, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}